Origenis
Origenis is a German biotech company specializing in AI-driven small molecule drug discovery, focusing on creating novel drug pipelines for diseases with unmet medical needs. Founded in 2005 from a management buyout of Morphochem AG's technology platform, Origenis integrates AI technology with wet lab synthesis and characterization to design highly selective small molecule drugs targeting difficult-to-reach tissues such as the brain and eye. Their proprietary platforms include BRAINstorm™ and EYEdeal™ technologies to overcome biological barriers. The company pursues target-, disease-, and organ-centric drug pipelines, including kinase and protease inhibitors, with a focus on neurodegeneration, brain cancer, antivirals, and ophthalmology. Origenis operates a cross-functional team and has collaborations with companies like Probiodrug (now Vivoryon) and Alcon, supporting its drug discovery efforts. The business model is primarily based on drug discovery services and partnerships, leveraging AI innovation platforms like MolMind® and MOREsystem®. Origenis is positioned as a pioneer in AI-guided drug discovery with a strong scientific leadership team and ongoing R&D in oncology and neurology.
Origenis
Origenis is a German biotech company specializing in AI-driven small molecule drug discovery, focusing on creating novel drug pipelines for diseases with unmet medical needs. Founded in 2005 from a management buyout of Morphochem AG's technology platform, Origenis integrates AI technology with wet lab synthesis and characterization to design highly selective small molecule drugs targeting difficult-to-reach tissues such as the brain and eye. Their proprietary platforms include BRAINstorm™ and EYEdeal™ technologies to overcome biological barriers. The company pursues target-, disease-, and organ-centric drug pipelines, including kinase and protease inhibitors, with a focus on neurodegeneration, brain cancer, antivirals, and ophthalmology. Origenis operates a cross-functional team and has collaborations with companies like Probiodrug (now Vivoryon) and Alcon, supporting its drug discovery efforts. The business model is primarily based on drug discovery services and partnerships, leveraging AI innovation platforms like MolMind® and MOREsystem®. Origenis is positioned as a pioneer in AI-guided drug discovery with a strong scientific leadership team and ongoing R&D in oncology and neurology.